FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule‐stabilizing effect

Platinum‐based regimens are the most widely used chemotherapy regimens, but cancer cells often develop resistance, which impedes therapy outcome for patients. Previous studies have shown that fibroblast growth factor 13 (FGF13) is associated with resistance to platinum drugs in HeLa cells. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hang, Wang, Handong, Qie, Anran, Wang, Jiaqi, Liu, Yueping, Gu, Guoqiang, Yang, Jing, Zhang, Hanqiu, Pan, Wensen, Tian, Ziqiang, Wang, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586689/
https://www.ncbi.nlm.nih.gov/pubmed/34533854
http://dx.doi.org/10.1111/cas.15137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586689/
https://www.ncbi.nlm.nih.gov/pubmed/34533854
http://dx.doi.org/10.1111/cas.15137

Ejemplares similares